Acetaminophen Market Share

North American Market Statistics

North America industry is likely to account for largest revenue share of 37% by 2037. Market growth in the region is also expected due to the presence of a robust healthcare infrastructure, and a focus on promoting quality health solutions. Large investments have been made by top industry bigwigs in R&D in North America, making great strides even in the acetaminophen market.

Especially in the U.S., viral infections like respiratory infections, influenza, etc are on the rise across all age groups. Spread easily through droplets in the air, there is a dependency on flu-related medications. Acetaminophen is the primary medication prescribed to these patients, and companies globally supply this country with this medication. With the growing geriatric population and age-related ailments on the rise, Acetaminophen may help alleviate the pain, without any major side effects. Approximately, 21% of the U.S. population lives in chronic pain. Modern life, alongside excessive screen time, is responsible for a high number of cases of chronic migraines in the area. Acetaminophen is prescribed for these cases as well, which is expected to drive up the growth trajectory of the market in the U.S.

APAC Market Analysis

By 2037, Asia Pacific acetaminophen market is likely to dominate over 32% revenue share, owing to the increasing population and general health issues in the area. Government campaigns held in public health interest to increase general health awareness, and make quality healthcare accessible are the market drivers for acetaminophen in this region. Acetaminophen is also sold in combination with other pain-relieving drugs, that are utilized regularly by patients in Asia Pacific.

In China, with the increased availability of generic medication, along with stiff competition from different acetaminophen manufacturers, there is still a lot of room in the acetaminophen market, as the growing pharmaceutical demands are challenging to meet. The population explosion, packed with the chronic disease burden is expected to take a toll on the already truncated healthcare system in the future. This region too experiences a high chronic pain rate, with 25.9% reeling with its effects on a daily basis. Access to Acetaminophen is expected to ease the self-resolving symptoms and provide a quick and convenient resolution, allowing for more serious cases to be addressed.